A new synthetic erythropoietin-type hormone, Rebligen, used to treat chemotherap

Question

A new synthetic erythropoietin-type hormone, Rebligen, used to treat chemotherapy-induced anemia in cancer patients was tested in a study of 48 adult cancer patients undergoing chemotherapeutic treatment. Half the patients received Rebligen and half received a placebo. Changes in hemoglobin (in mg/dl) from before administration of the drug or placebo to one week after the last administration of the drug or placebo were recorded. Is there evidence that Rebligen has an effect on the hemoglobin levels? The hypotheses for this test can be stated as follows: H0: Rebligen does not have an effect on the hemoglobin levels Ha: Rebligen does have an effect on the hemoglobin levels For this scenario state what a Type I Error would be. We conclude that a)____________________________________________________ , when actually b)________________________________________________________ .

Explanation / Answer

A Type 1 Error is a false positive -- i.e. you falsely reject the (true) null hypothesis.

We conclude that a) Rebligen does have an effect on the hemoglobin levels, when actually b) Rebligen does not have an effect on the hemoglobin levels

Related Questions

Navigate

• Browse (All)
• Browse A
• Subjects

Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.